Jazz Pharmaceuticals Plc (JAZZ): Russell J. Cox , EVP & COO of Jazz Pharmaceuticals Plc sold 4,000 shares on Apr 12, 2016. The Insider selling transaction was reported by the company on Apr 13, 2016 to the Securities and Exchange Commission. The shares were sold at $136.98 per share for a total value of $547,920.00 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Jazz Pharmaceuticals plc – Ordinary Shares is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 124 from a previous price target of $140 . The Rating was issued on Feb 24, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Initiated by Wells Fargo to Outperform. The Rating was issued on Feb 19, 2016.
Currently the company Insiders own 4.2% of Jazz Pharmaceuticals plc – Ordinary Shares shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -0.69%.Institutional Investors own 91.65% of Jazz Pharmaceuticals plc – Ordinary Shares shares.During last six month period, the net percent change held by insiders has seen a change of -4.26%.
Shares of Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -1.82 points or -1.30% at $138.19 with 6,20,072 shares getting traded. Post opening the session at $140.25, the shares hit an intraday low of $137.05 and an intraday high of $141.14 and the price vacillated in this range throughout the day. The company has a market cap of $8,455 M and the number of outstanding shares has been calculated to be 6,11,84,623 shares. The 52-week high of Jazz Pharmaceuticals plc – Ordinary Shares is $194.73 and the 52-week low is $108.5.